NCT04624256 2026-03-13
GARUDA
Jonsson Comprehensive Cancer Center
Phase NA Active not recruiting
Clinical Trials
21 trialsNCT04644770 2026-03-13
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT05616650 2026-03-13
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT05361798 2026-03-12
T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT06523634 2026-03-12
STEREOBED
Jules Bordet Institute
Phase NA Recruiting
NCT07451795 2026-03-05
SHARP
Fudan University
Phase 2 Recruiting
NCT04423211 2026-03-02
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT03159676 2026-02-25
Proton-Based Stereotactic Ablative Body Radiotherapy for Prostate Cancer
Mayo Clinic
Completed
NCT07426055 2026-02-23
PRO-BOOST-LC
Affidea Nu-med Center of Oncological DIagnostics and Therapy
Phase 2/3 Not yet recruiting
NCT04081428 2026-02-13
PRINToUT
NHS Lothian
Active not recruiting
NCT05320406 2026-02-12
REVELUTION
Emory University
Phase 2 Active not recruiting
NCT07393867 2026-02-06
ARPEGGIO
Brigham and Women's Hospital
Phase 2 Not yet recruiting
NCT03902951 2026-02-05
Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT02016248 2026-02-02
SBRT Boost for Unfavorable Prostate Cancer'
MemorialCare Health System
Phase NA Recruiting
NCT05946213 2026-02-02
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NRG Oncology
Phase 3 Recruiting
NCT03796767 2026-01-28
SOAR
University of Utah
Phase 2 Active not recruiting
NCT06397703 2026-01-28
ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer
NYU Langone Health
Phase 2 Recruiting
NCT06205316 2026-01-20
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
Mayo Clinic
Phase 3 Recruiting
NCT05038332 2026-01-16
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
University of Michigan Rogel Cancer Center
Phase 2 Recruiting
NCT05053152 2026-01-14
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
NRG Oncology
Phase 2 Recruiting
NCT06378866 2025-12-26
DIVINE
Mayo Clinic
Phase 2 Recruiting